← Back to Search

Antigen Test

SARS CoV-2 Antigen Tests for COVID-19 (Chelsea_MA Trial)

Phase 1

Recruiting

Led By Irene Bosch, PhD

Research Sponsored by IDX20 Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

older than 12 years of age

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Chelsea_MA Trial Summary

This trial aims to use rapid tests to monitor the presence of SARS-CoV-2 antigens in elderly people, w/o symptoms, to detect positive cases quickly & design a safe monitoring schema for COVID-19.

Eligible Conditions

Coronavirus Disease

Chelsea_MA Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Chelsea_MA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Diagnostic tests results positive or negative

Chelsea_MA Trial Design

1Treatment groups

Experimental Treatment

Group I: PCR comparatorExperimental Treatment1 Intervention

Another molecular test like PCR will be done to confirm the positive and negative antigen test

0 / 1Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

IDX20 IncLead Sponsor

National Institute on Minority Health and Health Disparities (NIMHD)NIH

381 Previous Clinical Trials

1,215,056 Total Patients Enrolled

Irene Bosch, PhDPrincipal InvestigatorIDX20 Inc

Media Library

Abbott BinaxNow tests (Antigen Test) Clinical Trial Eligibility Overview. Trial Name: NCT05884515 — Phase 1

Coronavirus Disease Research Study Groups: PCR comparator

Coronavirus Disease Clinical Trial 2023: Abbott BinaxNow tests Highlights & Side Effects. Trial Name: NCT05884515 — Phase 1

Abbott BinaxNow tests (Antigen Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05884515 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this treatment received clearance from the Food and Drug Administration?

"There is limited data regarding safety and efficacy, so this treatment was assigned a rating of 1."

Answered by AI

Are there still openings in this research program for individuals?

"Right. Per the information available on clinicaltrials.gov, this trial is currently recruiting participants; it was initially posted December 13th 2021 and last modified June 1st 2023. The study seeks to enrol 1000 patients from one location."

Answered by AI

What is the maximum capacity of individuals able to be enrolled in this clinical trial?

"Affirmative. According to clinicaltrials.gov, this medical trial initiated on December 13th 2021 and is still actively recruiting participants. The study's goal is to acquire 1000 patients from a solitary centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of Home Use COVID-19 Frequent Antigen Testing and Data Reporting

2021. "Evaluation of Home Use COVID-19 Frequent Antigen Testing and Data Reporting". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05884515.